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Background:  Congestive Heart Failure (CHF) affects about 5.8 million patients in the United States with more than 55,000 deaths every year. All 
the contributing factors to the outcomes in CHF should be further assessed.
Methods:  We searched electronic medical records for patients hospitalized for CHF exacerbation from 1999 to 2009 in a university hospital in 
New York. These patients were divided into two groups based on who is the treating physician. The groups were those patients seen by Cardiology 
and/or CHF physicians and those only treated by General Internal Medicine (IM) physicians. The patients who had cardiac transplantation or left 
ventricular assist devices were excluded. The two groups were compared for their 60 day mortality and readmission rates.
Results:  There were 8,945 patients admitted for acute CHF out of which 2,071 patients were seen by Cardiologists or HF physicians (23%) versus 
6874 seen by IM physicians (77%). Patients treated by the cardiology/CHF doctors showed lower 60-Day mortality (6.2% Vs 9.7%, P<0.0001) and 
re-admission rates (21.5% Vs 25.9%, p<0.0001). On discharge these patients had a more optimized CHF treatment plan such as more prescriptions 
of beta blockers (76.7% vs. 68%, p<0.0001), ACE inhibitors (65.4% vs. 59.8%, p<0.0001), spironolactone (29.6% vs. 19.7%, p<0.0001) and 
hydralazine (14.1% vs. 12.6%, p<0.0001).
Conclusions:  Hospitalized CHF patients treated by cardiologists and CHF physicians showed better 60- day mortality and readmission outcomes, 
